Aurinia Pharmaceuticals Inc
$16.96
$0.00 (+0.00%)
$16.75Day Range$17.16
Key Statistics
Market Cap
$2.26B
Shares Outstanding
133.1M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Oct 21, 2009
Round Lot
100
Locale
US
Trading Data
Day Open
$17.06
Day High
$17.16
Day Low
$16.75
Volume
850.2K
VWAP
$16.89
Prev Close
$16.96
Transactions
--
Acc. Volume
--
About Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
PHARMACEUTICAL PREPARATIONSSIC 2834128 employees#140, 14315 - 118 AVENUE, EDMONTON, A0, T5L 4S6250-744-2487IPO Oct 21, 2009US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001600620
- Composite FIGI
- BBG000BCRJM5
- Share Class FIGI
- BBG001S68013
- Ticker Root
- AUPH
- SIC Code
- 2834
About Aurinia Pharmaceuticals Inc (AUPH) Stock
Aurinia Pharmaceuticals Inc (AUPH) closed the 2026-09-17 session at $16.96, up 0.00% versus the previous close (+0.00). The stock opened at $17.06 and traded between $16.75 and $17.16 during that session. Session trading volume was 850K shares. The volume-weighted average price (VWAP) is $16.89.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
Aurinia Pharmaceuticals Inc has a market capitalization of $2.26 billion. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. AUPH is listed on the XNAS exchange. The company employs approximately 128 people. Aurinia Pharmaceuticals Inc is headquartered in EDMONTON, A0. The recorded listing date is 2009-10-21.
On this page you can find market AUPH stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.